A national, multi-centre study evaluating Thrombotic Thrombocytopenia Syndrome (TTS) associated with ChAdOx1 (AZD1222) and other SARS-CoV-2 vaccines (viral vector and m-RNA)
- Funded by Australian Government (Australian Research Council)
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
N/AKnown Financial Commitments (USD)
$2,151,643.58Funder
Australian Government (Australian Research Council)Principal Investigator
Unspecified Unspecified UnspecifiedResearch Location
AustraliaLead Research Institution
N/AResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementationResearch Subcategory
Adverse events associated with immunizationSpecial Interest Tags
N/AStudy Type
ClinicalClinical Trial Details
Not applicableBroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
A condition of a blood clot with low platelets has been described in some patients after receiving COVID-19 vaccines, including the widely available ChAdOx1 vaccine. Known as thrombosis with thrombocytopenia syndrome (TTS), this condition presents with a wide spectrum of severity. Although it has an immunological basis, the underlying mechanisms is unknown and there are no known predictors for increased risk of TTS. Further understanding is needed to ensure safe COVID-19 vaccination.